- November 11, 2019
- Category: What's New
November 11, 2019 — Radiation oncology and nuclear medicine software developer DOSIsoft has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its MU2net software for independent secondary dose calculation for patient quality assurance.
MU2net is a quality control tool for external-beam radiation therapy. It independently verifies the dose calculation performed by the treatment planning system and checks for potential errors in patient plans. It is vendor neutral and, therefore, compatible with all current treatment techniques, according to DOSIsoft.
MU2net has already been used for several years in Europe. FDA clearance allows it to be used in the U.S.